Department of Dermatology, Ewha Womans University School of Medicine, Seoul, Korea.
Corresponding author: You Won Choi, Department of Dermatology, Ewha Womans University School of Medicine, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 158-710, Korea. Tel: 82-2-2650-5159, Fax: 82-2-2652-6925, uwon313@ewha.ac.kr
Drug eruptions are common problems in hospital inpatients and outpatients. Cutaneous drug reactions range from mild to severe and from those localized only to skin to those associated with systemic disease. Cutaneous drug reactions are also a challenging diagnostic problem since they can mimic a large variety of skin diseases, including viral exanthem, collagen vascular disease, neoplasia, bacterial infection, psoriasis, and autoimmune blistering disease, among others. Furthermore, determining a particular medication which caused an eruption is often difficult when the patient is taking multiple drugs. In this review, clinical manifestations of adverse cutaneous drug reactions are described. A morphologic approach to drug eruption includes those that are classified as exanthematous eruption, urticaria, pustular eruption, bullous eruption, fixed drug eruption, photosensitive eruption, skin necrosis, lichenoid eruption, cutaneous pseudolymphoma, lupus erythematosus, and hand-foot syndrome. And also, recently reported cutaneous adverse reactions associated with newly developed drugs, such as epidermal growth factor receptor inhibitors, low molecular weight tyrosine kinase inhibitors, tumor necrosis factor-alpha antagonists, sirolimus and granulocyte colony-stimulating factor, are discussed.
3. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. Fitzpatrick's dermatology in general medicine 2008;7th ed. New York, McGraw-Hill Medical Publishing.
4. Barbaud A, Gonçalo M, Bruynzeel D, Bircher A. European Society of Contact DermatitisGuidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001;45:321-328.
5. Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998;139:49-58.
9. Lee AY. Drug eruption probably caused by penicillin in milk. Korean J Dermatol 1986;24:514-517.
10. Ros AM, Juhlin L, Michaëlsson G. A follow-up study of patients with recurrent urticaria and hypersensitivity to aspirin, benzoates and azo dyes. Br J Dermatol 1976;95:19-24.
11. Rappersberger K, Hönigsmann H, Ortel B, Tanew A, Konrad K, Wolff K. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Invest Dermatol 1989;93:201-209.
13. Shin KS, Cho KH, Lee YS. Clinical study of hospitalized patients with drug eruption during a 10-year reriod (1975~1985). Korean J Dermatol 1987;25:176-182.
14. Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010;10:46-50.
15. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011;50:619-625.
16. Kwon TE, Kwon OS, Chung JH, Cho KH, Youn JI. A clinicopathological study of chronic cutaneous lupus erythematosus. Korean J Dermatol 1999;37:459-467.
17. Adachi A, Nagai H, Horikawa T. Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. Dermatology 2007;214:85-88.
19. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
21. Sung KJ, Jeong HG, Koh JK. Erythrodysesthesia syndrome due to fluorouracil. Korean J Dermatol 1990;28:450-455.
22. Suh EJ, Kim SH, Kim SW. A case of excess granulation tissue response during etretinate therapy. Korean J Dermatol 1986;24:464-468.
23. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433.
27. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf 2004;27:1081-1092.
28. Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 2003;17:23-28.
29. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
30. Jang YH, Choi JH, Lim HY, Lee ES. Study of clinical features of cutaneous side effects associated with ZD 1839. Korean J Dermatol 2005;43:22-28.
31. Chung WK, Chang SE, Ryu MH, Lee MW, Choi JH, Moon KC, et al. Clinical features of the cutaneous adverse events induced by combination chemotherapy that includes cetuximab (Erbitux®). Korean J Dermatol 2008;46:1478-1487.
32. Chang GC, Yang TY, Chen KC, Yin MC, Wang RC, Lin YC. Complications of therapy in cancer patients. Case 1: paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:4646-4648.
33. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
35. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-206.
36. Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002;117:620-622.
38. Konstantopoulos K, Papadogianni A, Dimopoulou M, Kourelis C, Meletis J. Pityriasis rosea associated with imatinib (STI571, Gleevec). Dermatology 2002;205:172-173.
40. Bae YI, Yun SJ, Lee JB, Kim SJ, Lee SC, Won YH. A case of psoriasiform drug eruption induced by imatinib mesylate (Gleevec™). Korean J Dermatol 2009;47:722-725.
41. Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med 2006;354:2623-2624.
42. Ugurel S, Hildenbrand R, Dippel E, Hochhaus A, Schadendorf D. Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer 2003;88:1157-1159.
45. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-1324.
56. Prendiville J, Thiessen P, Mallory SB. Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy. Pediatr Dermatol 2001;18:417-421.
57. Dereure O, Bessis D, Lavabre-Bertrand T, Exbrayat C, Fegueux N, Biron C, et al. Thrombotic and necrotizing panniculitis associated with recombinant human granulocyte colony-stimulating factor treatment. Br J Dermatol 2000;142:834-836.
58. Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors: a review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol 1994;130:77-81.
A Case Report of Gamiseungmagalgeun-tang for a Cutaneous Adverse Drug Reaction in a Patient with Intracerebral Hemorrhage Eun-joo Seok, Junghwa Hong, Youngju Rhee, Jae-hyuk You, Jin-young Lee, Dong-jun Choi The Journal of Internal Korean Medicine.2024; 45(2): 278. CrossRef
Cutaneous adverse drug reactions Eun Hye Lee, Yong Hyun Jang Journal of the Korean Medical Association.2023; 66(1): 41. CrossRef
